The CEO and CFO of rare disease drugmaker Alexion just left the company
Alexion, a company that makes treatments for rare diseases, said on Monday that Chief Executive David Hallal had resigned, effective immediately, and named board member David Brennan as interim CEO.
The company also said Chief Financial Officer Vikas Sinha left to pursue other opportunities, effective immediately, and would be succeeded by David Anderson, who was earlier CFO at Honeywell International Inc.
The departures come at a moment of "great corporate strength and momentum," Alexion chairman Dr. Leonard Bell said in a call Monday. The company has not released its third-quarter 10-Q. The company said it expects to file that by January 2017.
Alexion had disclosed last month that it was investigating allegations made by a former employee regarding sales practices involving its flagship and costly blood disorder drug Soliris.
The company said on Monday the investigation had not identified any facts that require Alexion to update its previously reported historical results at this point in time.
Markets Insider
(Reuters reporting by Ankur Banerjee in Bengaluru; Editing by Sriraj Kalluvila)
Next Story
I spent $2,000 for 7 nights in a 179-square-foot room on one of the world's largest cruise ships. Take a look inside my cabin.
Saudi Arabia wants China to help fund its struggling $500 billion Neom megaproject. Investors may not be too excited.
Colon cancer rates are rising in young people. If you have two symptoms you should get a colonoscopy, a GI oncologist says.
Indian Army unveils selfie point at Hombotingla Pass ahead of 25th anniversary of Kargil Vijay Diwas
IndiGo places order for 30 wide-body A350-900 planes
Markets extend gains for 5th session; Sensex revisits 74k
Top 10 tourist places to visit in Darjeeling in 2024
India's forex reserves sufficient to cover 11 months of projected imports
